Search
for
Sort by
Research 31–60 of 1000+
- Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides as 5.alpha.-Reductase Inhibitors and Antiandrogens
- Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
- Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors
- Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
- An Old Problem with a New Cause-5 Alpha Reductase Inhibitors and Persistent Sexual Dysfunction
- Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- An update on the use of 5alpha-reductase inhibitors
- Long-Term Experience With 5-alpha-Reductase Inhibitors.
- Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic?
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
- The connection of 5-alpha reductase inhibitors to the development of depression
- Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
- Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target
- Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Bladder cancer survival in men using 5-alpha-reductase inhibitors
- Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara city/Iraq
- 5‐Alpha reductase inhibitor related litigation: A legal database review
- IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
- The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
- Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors